MedTrace Logo

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

NCT03834220 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2024-02-07

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.

Conditions

Interventions

DRUG

Debio 1347

Debio 1347 oral tablets.

Sponsors & Collaborators

  • Caris Life Sciences

    collaborator INDUSTRY

  • Optimal Research (Just In Time sites)

    collaborator UNKNOWN

  • Debiopharm International SA

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-22
Primary Completion
2020-12-31
Completion
2022-01-04
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Brazil
  • Bulgaria
  • Croatia
  • Czechia
  • Denmark
  • Finland
  • France
  • Greece
  • Netherlands
  • Norway
  • Philippines
  • Poland
  • Romania
  • Russia
  • Singapore
  • South Korea
  • Spain
  • Taiwan
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03834220 on ClinicalTrials.gov